Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G4EK
|
|||
| Drug Name |
PMID28454500-Compound-50
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Tsukuba University, JapaKyorin Pharmaceutical Co., Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H9NO4S
|
|||
| Canonical SMILES |
C(C(C(=O)O)N)SCC(=O)O
|
|||
| InChI |
1S/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
|
|||
| InChIKey |
GBFLZEXEOZUWRN-VKHMYHEASA-N
|
|||
| CAS Number |
CAS 638-23-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:16163
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cysteines of Keap1 (KEAP1 Cysteines) | Target Info | Modulator | [1] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [1] | |
| Target's Patent Info | Cysteines of Keap1 (KEAP1 Cysteines) | Target's Patent Info | [1] | |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.